Lyell Immunopharma, Inc.
NASDAQ: LYEL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lynn Seely
- Employees
- 161
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $303.3M
- Website
- https://www.lyell.com
Loading LYEL…
Loading profile data…Frequently asked questions about LYEL
What does Lyell Immunopharma, Inc. (LYEL) do?
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is...
Where does LYEL trade?
Lyell Immunopharma, Inc. (LYEL) trades on the NASDAQ.
What sector is LYEL in?
Lyell Immunopharma, Inc. (LYEL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Lyell Immunopharma, Inc.?
Lynn Seely is the chief executive officer of Lyell Immunopharma, Inc. (LYEL).
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc. is headquartered in United States.
Does LYEL pay a dividend?
Lyell Immunopharma, Inc. (LYEL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LYEL go public?
Lyell Immunopharma, Inc. (LYEL) completed its initial public offering in 2021.